Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06479057

PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy

PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.

This is an observational cohort study in the context of a quality-of-care initiative.

It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.

Secondary study endpoints include:

  • To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log)
  • To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire)
  • To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL)
  • To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30)
  • To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI)
  • To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS)
  • To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI)
  • To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22)
  • To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log)
  • To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log)
  • To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires.
  • To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers)
  • To plan for Maintenance of the pathway through a cost effectiveness analysis.
  • To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population
  • To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population
  • To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population
  • To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT)
  • To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population.
  • To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS)

This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.

Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histological confirmation of cancer (any cancer type, any stage)
  • Age ≥ 18 years old
  • Received an integrated supportive care need assessment.
  • Sign the consent form for the PROACT study.

Exclusion criteria

  • Absence or inability of written consent from the patient.
  • Does not understand or speak French.

Treatment and study plan

Supportive Care Pathway

Other

All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.

Primary outcomes

  1. Patient distress

    Time frame: over a 12-week period after the integrated supportive care needs assessment.

    Patient distress collected with NCCN Distress Thermometer

  2. Patient unmet needs

    Time frame: over a 12-week period after the integrated supportive care needs assessment.

    Patient unmet needs collected with problem list from NCCN Distress thermometer

Secondary outcomes

  1. Reach of the pathway

    Time frame: week 12

    Proportion of patients who accepted the supportive care needs assessment (descriptive numbers from attendance log)

  2. Diversity of pathway participants

    Time frame: week 12

    Socioeconomic characteristics of participants in the pathway measure by a self-reported socioeconomic questionnaire

  3. Impact of the pathway in overall health status

    Time frame: week 12, and 24

    Overall health status measured by the EQ-ED-5L

  4. Impact of the pathway in Quality of life

    Time frame: week 12, and 24

    Quality of life measured by the EORTC QLQ C30

  5. Impact of the pathway in symptom burden

    Time frame: week 12, and 24

    Symptom burden measured by the MDASI Questionnaire.

  6. Impact of the pathway on anxiety levels

    Time frame: week 12, and 24

    Anxiety measured by HADS

    • only for patients reporting anxiety at baseline
  7. Impact of the pathway on insomnia levels

    Time frame: week 12, and 24

    Insomnia measured by ISI

    *only for patients reporting insomnia at baseline

  8. Impact of the pathway on sexual health

    Time frame: week 12, and 24

    Sexual health measured by EORTC SHQ-C22

    *only for patients reporting sexual dysfunction at baseline

  9. Adoption of Physician

    Time frame: week 12

    Proportion of physicians referring patients to the supportive care pathway (descriptive numbers from referral logs)

  10. Adoption of Patient

    Time frame: week 12

    Proportion and of patients that fully adopted each supportive care intervention (e.g.; in the after cancer pathway: attendance to consultations/seminaries/classes, completion of a supportive care program, usage data for Resilience app).

  11. Patient Experience

    Time frame: week 12

    Patient experience measured by the PACIC questionnaire.

  12. Patient Satisfaction with the pathway

    Time frame: week 12

    Patient satisfaction measured by an ad hoc satisfaction questionnaire

  13. Provider Experience - Qualitative evaluation

    Time frame: week 12

    Focus groups with healthcare providers to explore overall experience, workload and implementation challenges

  14. Patient Satisfaction/Experience - Qualitative evaluation

    Time frame: week 12

    Focus groups with patient to explore overall experience and implementation challenges

  15. Maintenance of the pathway through a cost effectiveness analysis (QALYs)

    Time frame: week 12

    Maintenance of the pathway through a cost effectiveness analysis. Costs from the perspective of the French national health insurance will be assessed during the study period. This will be calculated by administrative data review of internal allocated resources for pathway delivery and estimated costs of use of hospital services (unplanned hospitalization, consultations, and emergency visits recorded in the electronic medical records).

    QALYs (quality-adjusted life years) will be measured using utility values derived from the EuroQol-5D (EQ-5D-5L) (https://euroqol.org/) for French general population (Andrade et al. PharmacoEconomics 2020). QALYs will be computed combining survival time by utility values.

  16. Impact of the pathway on Intestinal Symptom

    Time frame: week 24

    Intestinal Symptoms measured by LARS score.

    *only for patients with digestive cancer

  17. Impact of the pathway on Anal incontinence

    Time frame: week 24

    Anal incontinence measured by Wexner score.

    *only for patients with digestive cancer

  18. Impact of the pathway on Urinary symptoms

    Time frame: week 24

    Urinary symptoms measured by USP score.

    *only for patients with digestive cancer

  19. Impact of the pathway on Functional Assessment of Cancer Therapy-Bone Marrow Transplant

    Time frame: week 12, week 24

    Functional Assessment of Cancer Therapy-Bone Marrow Transplant measured by FACT-BMT score.

    *only for patients with Hematologic Cancer

  20. Impact of the pathway on caregiver burden

    Time frame: week 12

    Caregiver burden measured by Montgomery Borgatta Caregiver Burden Scale.

  21. Impact of the pathway on healthcare professionals participating in the pathway to screen vulnerability and prevent treatment

    Time frame: week 12

    Healthcare professionals measured by F-SUS Score

Study contacts

Contact information is provided by the study sponsor or research team.

Aude BARBIER

CONTACT

[email protected]

+33 (0)6 44 12 47 75

Maria Alice BORINELLI-FRANZOI

CONTACT

[email protected]

+33 (0)1 42 11 42 11

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Official study title

Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)

Acronym: PROACT

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jun 27, 2024
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.